Last reviewed · How we verify
subcutaneous tocilizumab
subcutaneous tocilizumab is a Small molecule drug developed by Centre Hospitalier Régional d'Orléans. It is currently FDA-approved. Also known as: Roactemra.
Subcutaneous tocilizumab is an interleukin-6 receptor alpha subunit inhibitor, classified as an INHIBITOR drug modality. It is used to treat conditions such as Rheumatoid Arthritis, Relapsing Polychondritis, and SARS CoV 2 Infection, among others.
At a glance
| Generic name | subcutaneous tocilizumab |
|---|---|
| Also known as | Roactemra |
| Sponsor | Centre Hospitalier Régional d'Orléans |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (PHASE1)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- subcutaneous tocilizumab CI brief — competitive landscape report
- subcutaneous tocilizumab updates RSS · CI watch RSS
- Centre Hospitalier Régional d'Orléans portfolio CI
Frequently asked questions about subcutaneous tocilizumab
What is subcutaneous tocilizumab?
Who makes subcutaneous tocilizumab?
Is subcutaneous tocilizumab also known as anything else?
What development phase is subcutaneous tocilizumab in?
Related
- Manufacturer: Centre Hospitalier Régional d'Orléans — full pipeline
- Also known as: Roactemra
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing